Announced details
Locally advanced non-small cell lung cancer, in combination with chemoradiotherapy and consolidation therapy with durvalumab
The primary endpoint is the 1-year progression-free survival rate. The disclosure states that previous clinical trial results confirmed enhanced antitumor effects of immune checkpoint inhibitors when used in combination with RS5614. The specific response rate is Not disclosed.
The investigator-initiated clinical trial is being conducted with the coordinating research institution and medical institutions in Japan. The trial has been selected for an AMED project. Capital and personnel relationships are Not disclosed.
The trial is being conducted at 12 medical institutions in Japan, with Hiroshima University Hospital serving as the coordinating research institution. AMED is a national research and development agency. Other details are Not disclosed.
12 medical institutions in Japan (detailed locations are Not disclosed)
AMED funding is expected to reduce the costs of this clinical trial. The costs related to this matter have already been incorporated into the full-year earnings forecast for the fiscal year ending March 2027.
The company does not address Contract Value / Offering price.
The Japan Agency for Medical Research and Development's (AMED) FY2026 Clinical Research and Clinical Trial Promotion Research Project and the results of a previous Phase II clinical trial disclosed on 5 March 2026
| Item | Details |
|---|---|
| Names of Products / Services Covered | PAI-1 inhibitor RS5614 |
| Counterparty | Hiroshima University Hospital, Okayama University Hospital, Shimane University Hospital, Hiroshima City Hiroshima Citizens Hospital, Tottori University Hospital, Kagawa University Hospital, Kochi University Hospital, National Hospital Organization Iwakuni Medical Center, Ehime University Hospital, Nara Medical University Hospital, Tohoku University Hospital, Hiroshima Prefectural Hospital, Japan Agency for Medical Research and Development (AMED) |
| Counterparty overview | The trial is being conducted at 12 medical institutions in Japan, with Hiroshima University Hospital serving as the coordinating research institution. AMED is a national research and development agency. Other details are Not disclosed. |
| Relationship with the Company | The investigator-initiated clinical trial is being conducted with the coordinating research institution and medical institutions in Japan. The trial has been selected for an AMED project. Capital and personnel relationships are Not disclosed. |
| Launch date | 16 July 2026 (first patient dosing; completed) |
| Applicable area | Locally advanced non-small cell lung cancer, in combination with chemoradiotherapy and consolidation therapy with durvalumab |
| Location | 12 medical institutions in Japan (detailed locations are Not disclosed) |
| Location scale | 12 medical institutions, 27 patients |
| Quantitative Effects | The primary endpoint is the 1-year progression-free survival rate. The disclosure states that previous clinical trial results confirmed enhanced antitumor effects of immune checkpoint inhibitors when used in combination with RS5614. The specific response rate is Not disclosed. |
| Impact on Business Performance | AMED funding is expected to reduce the costs of this clinical trial. The costs related to this matter have already been incorporated into the full-year earnings forecast for the fiscal year ending March 2027. |
| Source | The Japan Agency for Medical Research and Development's (AMED) FY2026 Clinical Research and Clinical Trial Promotion Research Project and the results of a previous Phase II clinical trial disclosed on 5 March 2026 |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The trial was selected for the Japan Agency for Medical Research and Development's (AMED) FY2026 Clinical Research and Clinical Trial Promotion Research Project, and previous clinical trials and mouse lung cancer models confirmed enhanced antitumor effects when RS5614 was used in combination.